Guardant Health (GH) Competitors

$17.34
-0.25 (-1.42%)
(As of 04/23/2024 ET)

GH vs. VCYT, VRDN, RDNT, FTRE, FLGT, CSTL, AMPH, DNA, GERN, and GLPG

Should you be buying Guardant Health stock or one of its competitors? The main competitors of Guardant Health include Veracyte (VCYT), Viridian Therapeutics (VRDN), RadNet (RDNT), Fortrea (FTRE), Fulgent Genetics (FLGT), Castle Biosciences (CSTL), Amphastar Pharmaceuticals (AMPH), Ginkgo Bioworks (DNA), Geron (GERN), and Galapagos (GLPG). These companies are all part of the "medical" sector.

Guardant Health vs.

Guardant Health (NASDAQ:GH) and Veracyte (NASDAQ:VCYT) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their community ranking, dividends, earnings, media sentiment, analyst recommendations, institutional ownership, profitability, valuation and risk.

Guardant Health currently has a consensus target price of $40.40, suggesting a potential upside of 132.99%. Veracyte has a consensus target price of $29.00, suggesting a potential upside of 46.24%. Given Guardant Health's stronger consensus rating and higher possible upside, equities research analysts plainly believe Guardant Health is more favorable than Veracyte.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Guardant Health
0 Sell rating(s)
2 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.83
Veracyte
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60

Veracyte has lower revenue, but higher earnings than Guardant Health. Veracyte is trading at a lower price-to-earnings ratio than Guardant Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Guardant Health$563.95M3.74-$479.45M-$4.28-4.05
Veracyte$361.05M4.12-$74.40M-$1.03-19.25

In the previous week, Guardant Health had 6 more articles in the media than Veracyte. MarketBeat recorded 12 mentions for Guardant Health and 6 mentions for Veracyte. Guardant Health's average media sentiment score of 0.14 beat Veracyte's score of 0.11 indicating that Guardant Health is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Guardant Health
4 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
2 Very Negative mention(s)
Neutral
Veracyte
2 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Veracyte has a net margin of -20.61% compared to Guardant Health's net margin of -85.02%. Veracyte's return on equity of -2.02% beat Guardant Health's return on equity.

Company Net Margins Return on Equity Return on Assets
Guardant Health-85.02% -301.94% -27.65%
Veracyte -20.61%-2.02%-1.89%

Veracyte received 168 more outperform votes than Guardant Health when rated by MarketBeat users. Likewise, 72.88% of users gave Veracyte an outperform vote while only 68.59% of users gave Guardant Health an outperform vote.

CompanyUnderperformOutperform
Guardant HealthOutperform Votes
262
68.59%
Underperform Votes
120
31.41%
VeracyteOutperform Votes
430
72.88%
Underperform Votes
160
27.12%

Guardant Health has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500. Comparatively, Veracyte has a beta of 1.62, indicating that its stock price is 62% more volatile than the S&P 500.

92.6% of Guardant Health shares are held by institutional investors. 6.2% of Guardant Health shares are held by insiders. Comparatively, 2.6% of Veracyte shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Guardant Health and Veracyte tied by winning 9 of the 18 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GH vs. The Competition

MetricGuardant HealthMedical laboratories IndustryMedical SectorNASDAQ Exchange
Market Cap$2.11B$1.67B$4.84B$7.49B
Dividend YieldN/A1.90%5.51%3.98%
P/E Ratio-4.057.47240.8920.93
Price / Sales3.74138.622,419.7589.75
Price / CashN/A481.0432.1727.25
Price / Book12.943.384.684.31
Net Income-$479.45M-$168.49M$102.52M$213.83M
7 Day Performance5.80%2.47%0.41%1.35%
1 Month Performance0.52%-7.21%-5.79%-4.08%
1 Year Performance-24.84%-15.65%10.14%7.92%

Guardant Health Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VCYT
Veracyte
3.4995 of 5 stars
$18.92
-2.3%
$29.00
+53.3%
-14.3%$1.42B$361.05M-18.37815
VRDN
Viridian Therapeutics
1.2083 of 5 stars
$15.09
-3.5%
$36.60
+142.5%
-52.0%$947.20M$310,000.00-2.8494
RDNT
RadNet
3.1673 of 5 stars
$47.89
+0.2%
$53.67
+12.1%
+74.6%$3.28B$1.62B-2,393.3010,288
FTRE
Fortrea
0.7218 of 5 stars
$36.81
-3.2%
$37.29
+1.3%
N/A$3.29B$3.11B0.0018,000Positive News
FLGT
Fulgent Genetics
4.3302 of 5 stars
$20.72
-0.1%
$30.00
+44.8%
-31.3%$619.53M$289.21M-3.671,184
CSTL
Castle Biosciences
2.0313 of 5 stars
$18.94
-1.5%
$31.00
+63.7%
-17.6%$519.90M$219.79M-8.77610
AMPH
Amphastar Pharmaceuticals
4.8374 of 5 stars
$40.90
+0.3%
$66.00
+61.4%
-6.7%$1.97B$644.40M15.851,761Positive News
DNA
Ginkgo Bioworks
1.1523 of 5 stars
$0.92
-3.2%
$2.20
+139.8%
-33.5%$1.97B$251.46M-1.951,218
GERN
Geron
2.943 of 5 stars
$3.58
+3.8%
$5.33
+49.0%
+31.1%$1.96B$240,000.00-10.85141
GLPG
Galapagos
0.4747 of 5 stars
$29.49
-1.0%
$34.50
+17.0%
-24.1%$1.94B$259.40M-12.881,123Analyst Report

Related Companies and Tools

This page (NASDAQ:GH) was last updated on 4/24/2024 by MarketBeat.com Staff

From Our Partners